Zug, Switzerland: Galderma will present new data on Relfydess (RelabotulinumtoxinA) – the first and only ready-to-use liquid neuromodulator created using PEARL™ Technology, which has now launched in multiple countries in Europe – including results from the phase IIIb RELAX trial, reinforcing its long-term efficacy and high patient satisfaction, as seen …
